FDA and Direct-to-Consumer Genetics Testing

When 23andMe launched its first genetic test to the consumer market in 2013, the U.S. Food and Drug Administration (FDA) quickly ordered the company to stop marketing the test without necessary approvals as a medical device, citing the potential for… Read »

Dsuvia — Much Needed Analgesic or Potential New Contributor to the Opioid Crisis?

Does the United States really need another opioid drug, given the enormous public health crisis of opioid addiction facing the country today? Many experts are asking this question about the FDA’s approval in November of Dsuvia (sufentinil), a powerful opioid … Read »

Big Oncology Mergers Kick Off 2019

Each January, a large portion of the international healthcare industry descends on San Francisco for the JP Morgan Healthcare Conference and a variety of other concurrent industry events. The sentiment of the nearly 10,000 attendees — largely influenced by partnering… Read »

Differentiation Through Digital  

Digital technology is becoming increasingly important in the healthcare space. This was clearly reflected by the growing number of companies and events focused on the digital healthcare sector during JP Morgan/Biotech Week in San Francisco and new conferences dedicated to… Read »

Multiple Myeloma: The View from ASH 2018

Multiple myeloma (MM) is a deadly bone marrow cancer. In recent years, the treatment landscape for this disease has improved considerably. However, most patients still relapse and the need for new and better therapeutic options endures.   Encouraging news about… Read »

Happy New Year — Some Thoughts on the Year to Come

Welcome to 2019. We hope you enjoyed the holidays and look forward to meeting and greeting many of you next week in San Francisco for Biotech Week. Several members of the Bionest team will be in attendance, and if you’d… Read »

New Approaches to an Earlier Alzheimer’s Disease Diagnosis

We have written previously about the need for earlier diagnosis for Alzheimer’s disease (AD) and other dementias, a capability that could both aid in the discovery and the development of new therapies, and increase the chances for better patient outcomes… Read »

Neuromuscular Drug Development Summit

At the end of October, we attended the inaugural Neuromuscular Drug Development Summit. This new meeting brought together thought leaders from industry, academia, and the patient advocacy community to discuss scientific progress and issues affecting companies developing drugs for these… Read »

No Signs of Slowdown in NGS Sequencing Market

A couple of recent announcements in the next-generation sequencing (NGS) market got our attention as strong signs that both technology and applications are rapidly diversifying within that arena. It’s continued evidence that the NGS market is not only expanding rapidly,… Read »

Report on ESMO 2018 – Part Two

We recently returned from the European Society for Medical Oncology (ESMO) meeting where conference news highlighted the increased movement of targeted therapies and immunotherapies into adjuvant and early-stage cancer settings. Read our earlier report on combination therapy trials in melanoma,… Read »

1 2 3 4 15